The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1289-1297

  Andersen, Mads Hald ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antigen; IDO; Immune suppression; PIVAC 11; Supporter T cells

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; CONGRESSES AS TOPIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84865743717     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1234-4     Document Type: Review

References (51)

1. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, Thor SP (2009) Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 119(8):2245-2256
2. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL (2009) IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 183(4):2475-2483
3. Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL (2005) A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 17(7):909-919 (Pubitemid 41417958)
4. Bauer TM, Jiga LP, Chuang JJ, Randazzo M, Opelz G, Terness P (2005) Studying the immunosuppressive role of indoleamine 2,3- dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 18(1):95-100 (Pubitemid 41742952)
5. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM (2007) HIV inhibits CD4? T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109(8):3351-3359 (Pubitemid 46572523)
6. Chen Z, O'Shea JJ (2008) Th17 cells: A new fate for differentiating helper T cells. Immunol Res 41(2):87-102
7. Cherayil BJ (2009) Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 15(9):1391-1396
8. Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, DuHadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, Karp CL (2012) Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis 205(1):152-161
9. Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34(6):524-531 (Pubitemid 350236303)
10. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G (2011) Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination. Vaccine 29(12):2242-2247
11. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196(4):459-468
12. Furset G, Floisand Y, Sioud M (2008) Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology 123(2):263-271
13. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-Tryptophan correlates with antitumor responses. Cancer Res 67(2):792-801 (Pubitemid 46192220)
14. Jozkowicz A, Was H, Dulak J (2007) Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 9(12):2099-2117 (Pubitemid 350059009)
15. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA (2002) Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169(4):1984-1992 (Pubitemid 34857662)
16. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P (2007) Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111(4):2152-2154 (Pubitemid 351451527)
17. Makala LH, Baban B, Lemos H, El-Awady AR, Chandler PR, Hou DY, Munn DH, Mellor AL (2011) Leishmania major attenuates host immunity by stimulating local indoleamine 2,3- dioxygenase expression. J Infect Dis 203(5):715-725
18. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5):787-798
19. Mellor AL, Munn DH (2008) Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8(1):74-80
20. Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine,3-dioxygenase inhibitory compound D-1-methyltryptophan. Cancer Res 67(15):7082-7087 (Pubitemid 47206533)
21. Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H (2006) Generation of tumor-specific T-cell therapies. Blood Rev 20(2):61-69
22. Muller AJ, Prendergast GC (2007) Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 7(1):31-40 (Pubitemid 46345506)
23. Munir S, Larsen SK, Iversen TZ, Svane IM, Donia M, Klausen TW, Thor Straten P, AndersenMH(2012) Natural CD4 T cell responses against Indoleamine 2,3-dioxygenase. PLoS ONE (in press
24. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147-1154 (Pubitemid 46718399)
25. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3- dioxygenase. Immunity 22(5):633-642 (Pubitemid 40719198)
26. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280-290 (Pubitemid 39071633)
27. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191-1193 (Pubitemid 28406294)
28. O'Quinn DB, Palmer MT, Lee YK, Weaver CT (2008) Emergence of the Th17 pathway and its role in host defence. Adv Immunol 99:115-163
29. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-Term tolerance by dendritic cells. Nat Immunol 12(9):870-878
30. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310(5749):850-855 (Pubitemid 41567343)
31. Popov A, Schultze JL (2007) IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 86(2):145-160
32. Prendergast GC, Metz R, Muller AJ (2009) IDO recruits Tregs in melanoma. Cell Cycle 8(12):1818-1819
33. Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Bistoni G, Rasi G, Velardi A, Fallarino F, Garaci E, Puccetti P (2006) Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108(7):2265-2274 (Pubitemid 44497509)
34. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25 CD4 regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6(4):345-352 (Pubitemid 41716771)
35. Sakaguchi S (2006) Regulatory T cells. Springer Semin Immunopathol 28(1):1-2 (Pubitemid 44267953)
36. Scheler M, Wenzel J, Tuting T, Takikawa O, Bieber T, von Bubnoff D (2007) Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? Am J Pathol 171(6):1936-1943
37. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117(9):2570-2582 (Pubitemid 47494358)
38. Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, Blazar BR, Mellor AL, Munn DH (2010) Reprogrammed foxp3(?) regulatory T cells provide essential help to support cross-presentation and CD8(?) T cell priming in naive mice. Immunity 33(6):942-954
39. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3? Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113(24):6102-6111
40. Sorensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, Thor SP, Andersen MH (2009) The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS ONE 4(9):e6910
41. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor SP, Andersen MH (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117(7):2200-2210
42. Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, Andersen MH (2011) Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 71(6):2038-2044
43. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ (2005) Broadly targeted human cytomegalovirusspecific CD4? and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202(5):673-685 (Pubitemid 41248418)
44. Thebault P, Condamine T, Heslan M, Hill M, Bernard I, Saoudi A, Josien R, Anegon I, Cuturi MC, Chiffoleau E (2007) Role of IFNgamma in allograft tolerance mediated by CD4? CD25? regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 7(11):2472-2482 (Pubitemid 47561604)
45. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269-1274 (Pubitemid 37279849)
46. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214(1):8-14 (Pubitemid 46032994)
47. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: A novel, active target. J Am Coll Surg 208(5):781-787
48. Xu H, Oriss TB, Fei M, Henry AC, Melgert BN, Chen L, Mellor AL, Munn DH, Irvin CG, Ray P, Ray A (2008) Indoleamine 2,3- dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci USA 105(18): 6690-6695 (Pubitemid 351754568)
49. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, Feng XH, Jetten AM, Dong C (2008) Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29(1):44-56
50. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263-274 (Pubitemid 40488632)
51. Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10(4):248-256